IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant:

Masahiro AOKI et al

Title:

VIRUS THERAPEUTIC DRUG

Appl. No.:

10/544,896

International

2/12/2004

Filing Date:

371(c) Date:

8/8/2005

Examiner:

Timothy E. BETTON

Art Unit:

1617

Conf. No.:

6474

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The listed documents were cited in the Supplemental European Search Report dated 4/3/2009, in corresponding European application 04710509.3. A copy of the search report is also cited herein.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

	MAY O 1 2009		Markolal
Date		Ву	1 JUNOUN

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5569 Facsimile: (202) 672-5399 Stephen B. Maebius Attorney for Applicant Registration No. 35,264